Affiliation:
1. Institute of Rheumatology, Na Slupi 4, 128 50 Prague 2, Czech Republic.
Abstract
Adalimumab (Humira® , Abbott Laboratories, IL, USA) is a biological, disease-modifying antirheumatic drug for the treatment of rheumatoid arthritis, psoriatic arthritis and potentially other inflammatory rheumatic disorders and autoimmune diseases. Adalimumab is a fully human immunoglobin G1 monoclonal antibody that binds specifically to tumor necrosis factor, thereby neutralizing the activity of this central cytokine in the rheumatoid arthritis disease process. Adalimumab’s efficacy and activity in the suppression of rheumatoid arthritis, both in combination with methotrexate or other disease-modifying antirheumatic drugs, and as monotherapy, is well established. It has been shown to be effective both in long-standing, moderate-to-severe rheumatoid arthritis and in early disease. In randomized controlled trials and open-label studies, clinical response from adalimumab was rapid (1–2 weeks) and has been sustained through 6 years. Adalimumab also improves quality of life and inhibits structural damage. The clinical remission rate of adalimumab plus methotrexate in early rheumatoid arthritis is nearly 50%. Adalimumab is generally well tolerated. In rheumatoid arthritis clinical trials, there were more injection site reactions with adalimumab compared with placebo. Cases of tuberculosis and opportunistic infections have been reported, and adequate screening and monitoring before and during therapy are recommended. Lymphoma incidence is probably identical to that observed in patients with severe rheumatoid arthritis. Induction of clinically significant autoimmune diseases is rare.
Subject
Geriatrics and Gerontology,General Medicine
Reference73 articles.
1. MacGregorAJ, Silman AJ: Rheumatoid arthritis and other synovial disorders. Classification and epidemiology. In:Rheumatology. Vol. 1, (3rd Edition).Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH (Eds). Mosby, Edinburgh, UK757–763 (2003).
2. The epidemiology of rheumatoid arthritis in Rochester, Minnesota, 1955-1985
3. KremersHM, Gabriel SE: Broad issues in the approach to rheumatic diseases. epidemiology of the rheumatic diseases. In:Kelly’s Textbook of Rheumatology: Vol. 1 (7th Edition)Harris Jr ED, Budd RC, Firestein GSet al. (Eds). Elsevier Saunders, PA, USA,407–425 (2005).
4. Epidemiology of rheumatoid arthritis: determinants of onset, persistence and outcome
5. Epidemiology and burden of illness of rheumatoid arthritis
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献